Billionaire Icahn Named ImClone Chairman, Interim CEO Resigns
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm searches for new CEO with biotech, drug development and commercialization experience.
You may also be interested in...
ImClone Board Members Demand Control Premium From Icahn
Latest salvo from Icahn prompts board to ask shareholders to reject billionaire’s demands.
Bristol’s Termination Of Dolan Follows Federal Monitor’s Recommendation
However, the company’s monitor and the U.S. Attorney for New Jersey conclude that Bristol has not violated a deferred prosecution agreement.
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.